A2 Biotherapeutics is thrilled to announce a significant funding milestone of $80 million, a strategic investment that will expedite the company’s mission to revolutionize cancer treatment through innovative cell therapy. Founded in 2018 by visionary leaders Alexander Kamb, Michael Gallo, and Paul Kang, A2 is dedicated to transforming medicine by targeting solid tumors—a challenging frontier in the field. The latest funding round, which brings the total capital raised since inception to an impressive $136 million, comes from a consortium of esteemed investors, including The Column Group, Vida Ventures, and Hartford HealthCare Endowment. This financial boost will facilitate the advancement of A2's cutting-edge technology that engineers T cells to specifically recognize and attack tumor cells that have lost crucial genetic material, thereby enabling rapid and selective destruction of malignant cells while sparing healthy tissues. The implications of this innovative approach hold tremendous promise for patients facing daunting cancer diagnoses. With this new infusion of funds, A2 aims to accelerate clinical development, enhance research capabilities, and expand its team of experts dedicated to making a tangible impact in oncology. “This investment validates our approach and underscores the confidence our investors have in our vision to tackle the complexities of solid tumors,” said CEO Alexander Kamb. A2 Biotherapeutics epitomizes the future of personalized medicine, and with substantial resources backing its quest, the company is poised to break new ground in the fight against cancer.
Revolutionizing Cancer Treatment: A2 Biotherapeutics Secures $80M in Series C Funding
Recently funded · $80.0M Series cBiotechnology
Get the full A2 Biotherapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series c rounds
Companies that recently closed a Series c round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  SOLIVIS | Series c | $16.0M | 1d ago |
| 2 |  SKAN Switzerland | Series c | $63.0M | 1d ago |
| 3 |
